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VIEWPOINT
ONLINE FIRST
Ethical Challenges of Preexposure
Prophylaxis for HIV
Jonathan S. Jay, JD, MA
Lawrence O. Gostin, JD
ON JULY 16, 2012, EMTRICITABINE/TENOFOVIR(Truvada; Gilead Sciences) became the first drugapproved by the US Food and Drug Adminis-tration (FDA) for preexposure prophylaxis
(PrEP) of human immunodeficiency virus (HIV) for adults
at high risk. Clinical trials have demonstrated that daily use
of oral antiretroviral drugs can reduce the risk of HIV ac-
quisition through sexual intercourse. With 50 000 new HIV
infections per year in the United States1 and 2 million per
year worldwide,2 PrEP could become a major component
of “combination prevention” along with condoms, coun-
seling, testing, and treatment.
Behavior and Effectiveness
Emtricitabine/tenofovir is only partially effective for HIV pre-
vention, with the Partners PrEP study of serodiscordant
couples reporting a 75% risk reduction in HIV transmis-
sion.3 The effectiveness of PrEP correlates with adherence;
the iPrEx study of male-to-male sexual contact reported more
than 90% protection among study participants with high ad-
herence,4 but 44% reduction in HIV transmission overall.5
Even a modest 44% reduction, however, would represent a
clear benefit in high-prevalence settings and sexual net-
works. Researchers must closely monitor the results of on-
going open-label studies of PrEP, as well as use in practice,
and if necessary, conduct pilot programs to increase adher-
ence over time.
If unsafe sex were to increase with PrEP, it could theo-
retically offset effectiveness in practice. Behavioral disinhi-
bition, however, was not observed in clinical trials. More-
over, a substantial increase in unsafe sex would have to occur
to offset the benefits of PrEP on a population level.
Cost-effectiveness
Daily emtricitabine/tenofovir in the United States has been
estimated to cost $10 000 per year, including screening and
physician visits.6 This cost is high compared with alterna-
tive prevention strategies. However, even high-price inter-
ventions become cost-effective when compared with the
greater cost (and morbidity) that would occur if individu-
als became infected.
At a health system level, comparative cost-effectiveness
should be a primary consideration for priority setting. As-
suming 44% effectiveness, one model estimated that emtri-
citabine/tenofovir would be cost-effective for those who en-
gage in male-to-male sexual contact who average 5 sexual
partners per year.6 Additional research is needed to com-
pare cost-effectiveness across different combination pre-
vention approaches.
Patient and Population-Level Risk
If patients who are HIV infected take emtricitabine/
tenofovir, drug resistance can occur, thereby compromis-
ing therapeutic options and possibly posing a public health
threat. Therefore, PrEP requires regular testing and re-
liable medication use. The FDA Amendments Act of 2007
empowers the agency to approve a drug subject to a Risk
Evaluation and Mitigation Strategy, including medical test-
ing. The FDA could have directed physicians to prescribe
and pharmacies to dispense this drug only to patients with
a negative HIV test result. Such stringent conditions, how-
ever, would reduce access. The FDA instead required the
manufacturer of emtricitabine/tenofovir to train and edu-
cate health care professionals and collect drug utilization
data. The FDA labeling recommends HIV testing at least
every 3 months, as well as symptom monitoring for acute
HIV-1 infection and toxicities (especially kidney impair-
ment and bone density loss).
Equity and Justice
Despite empowering patients and promoting the public’s
health, PrEP could exacerbate health care inequalities.
High cost and intense medical monitoring could exclude
individuals with low income, unstable housing, drug
dependence, or mental illness. This challenge is even
greater in low-income countries with limited resources
and infrastructure.
Early PrEP adopters are likely to include gay and bisexual
men and heterosexual serodiscordant couples with greater
education and resources. Extending PrEP to other groups
will require effective public health governance, along with
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research and innovation. Fortunately, a blueprint exists: an-
tiretroviral strategies for both HIV treatment and prevent-
ing mother-to-child transmission have relied on advances
in science, financing, access, and health care to achieve re-
markable success globally.
Underserved Populations. Reaching populations
with disproportionate HIV incidence, including young
black men who engage in male-to-male sexual contact, is
crucial to reduce HIV burdens and promote equity.
Although the Affordable Care Act will expand coverage,
it cannot ensure testing and PrEP for all vulnerable indi-
viduals. Prevention programs should explore synergies
with HIV testing campaigns, which currently link to
treatment, but they could also link to PrEP for HIV-
negative, high-risk individuals.
Women. The FDA approval includes at-risk women,
despite mixed evidence of PrEP effectiveness but clear
need: 25% of new HIV infections in the United States1 and
half worldwide2 occur in women. PrEP addresses the need
for a female-controlled prevention mechanism that can be
used without a male partner’s consent. The efficacy of oral
PrEP remains less certain for women than for men,
although the results of the VOICE study (clinicaltrials.gov
NCT00705679) are expected in 2013 and could alleviate con-
cerns raised by the FEM-PrEP study, which closed early due
to futility.7 A female-specific prevention method such as vagi-
nal microbicide could enhance the effectiveness of chemo-
prophylaxis among women. The CAPRISA 004 trial found
that topical tenofovir gel, used before and after sexual con-
tact, reduced HIV acquisition by 39%.8
Generalized Epidemics. Most new HIV infections
worldwide occur in developing countries experiencing
generalized epidemics. Although the United States is the
only country to have approved a PrEP indication, others
may soon follow. PrEP rollout represents a vital test for
governments, global health programs (eg, PEPFAR and
the Global Fund to Fight AIDS, Tuberculosis and
Malaria), and normative bodies (World Health Organiza-
tion). Cost and health care infrastructure could represent
major barriers to widespread PrEP availability. Planning
for regulatory review, financing, and implementation
must therefore continue.
Ethical Resource Allocation. Thousands of Americans
with HIV are currently on waiting lists for drug treatment,
even though effective treatment significantly reduces the risk
of transmission.9 Given scarce resources, what are the rela-
tive priorities between PrEP for healthy individuals and treat-
ment for currently infected individuals? Although these 2
uses may appear to entail inescapable trade-offs, expand-
ing treatment for all infected individuals (which is now
recommended),10 while selectively offering PrEP to high-
risk individuals, is the best public health strategy and could
lower health care costs in the long term.
Ethical Research. The FDA’s approval of PrEP will
trigger scrutiny of HIV prevention trials using placebo
controls. Beneficence requires researchers to minimize
risks to study participants—and while regulatory
approval alone does not determine the appropriate stan-
dard of care, it signals a strong evidence base and shifting
clinical norms. Offering PrEP to study participants, how-
ever, presents scientific and logistical research challenges,
with no consensus on how to balance conflicting obliga-
tions. Multistakeholder deliberations should proceed on
this topic.
Looking Ahead
Daily oral emtricitabine/tenofovir is likely just the first
iteration of PrEP interventions that will reach the market.
Dosing PrEP intermittently (before and after sexual expo-
sure, or only during periods of increased sexual activity),
rather than daily, could theoretically maintain effective-
ness for some users while reducing toxicity and cost.
Longer-acting PrEP products such as vaginal rings or
injectable agents could also reduce the daily burden for
PrEP users. With these biomedical advances, PrEP could
transform HIV prevention much like hormonal contra-
ception transformed family planning. Combination pre-
vention and universal treatment makes it possible to
dream of an “AIDS-free” generation.
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